Immunoglobulin chimeric monomer-dimer hybrids

Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S387300, C530S391700, C530S402000

Reexamination Certificate

active

10841250

ABSTRACT:
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

REFERENCES:
patent: 3941763 (1976-03-01), Sarantakis
patent: 4695623 (1987-09-01), Stabinsky
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5077204 (1991-12-01), Brake et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5162220 (1992-11-01), Oshima et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5234830 (1993-08-01), Oshima et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5482858 (1996-01-01), Huston et al.
patent: 5579277 (1996-11-01), Bolognsi et al.
patent: 5585089 (1996-11-01), Kelly
patent: 5591573 (1997-01-01), Whalen et al.
patent: 5605689 (1997-02-01), Ammann
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648240 (1997-07-01), Ammann et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5885821 (1999-03-01), Magota et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6068973 (2000-05-01), Barney et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6093799 (2000-07-01), Li et al.
patent: 6184344 (2001-02-01), Kent et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: 6310180 (2001-10-01), Tam
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6329176 (2001-12-01), Woldike et al.
patent: 6469136 (2002-10-01), Bray et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6518013 (2003-02-01), Barney et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2003/0053984 (2003-03-01), Tschopp et al.
patent: 2003/0119727 (2003-06-01), Dennis et al.
patent: 2003/0180287 (2003-09-01), Gambotz et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0077022 (2004-04-01), Feige et al.
patent: 2005/0027109 (2005-02-01), Mezo et al.
patent: 2005/0037941 (2005-02-01), Bitonti et al.
patent: 0 325 262 (1989-07-01), None
patent: 2 641 468 (1990-07-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-02-01), None
patent: WO 90/11364 (1991-10-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 00/18881 (2000-05-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/36637 (2001-05-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/18417 (2002-03-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/089828 (2002-11-01), None
patent: 03/077834 (2003-09-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 2004/03176 (2004-01-01), None
patent: WO 2004/006962 (2004-01-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
US 6,020,459, 02/2000, Barney et al. (withdrawn)
Baru et al. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene 1995, vol. 161, p. 143-150.
International Search Report for PCT/US04/14064 dated Apr. 6, 2006.
Ghetie et al., “Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FcRn,”Annu. Rev. Immunol., 18:739-766 (2000).
Jelesarov et al., “Thermodynamic Characterization of the Coupled Folding and Association of Heterodimeric Coiled Coils (Leucine Zippers),”J. Mol. Biol., 263:344-358 (1996).
Swaminathan et al., “Affinity Purification of Recombinant Interferon-α on a Mimetic Ligand Adsorbent,”Protein Expression and Purification, 15:236-242 (1999).
Aruffo et al., “CD44 Is the Principal Cell Surface Receptor for Hyaluronate,”Cell61:1303 (1990).
Ashkenazi et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA88:10535 (1991).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. Biol. Chem. 266:23060 (1991).
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1Fragments,”Science229:81 (1985).
Byrn et al., “Biological properties of a CD4 immunoadhesin,”Natur, 344:667 (1990).
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature337:525 (1989).
Chalupny et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins,”Proc. Natl. Acad. Sci. USA89:10360 (1992).
Dawson et al., “Synthesis of Native Proteins by Chemical Ligation,”Annu. Rev. Biochem. 69:923 (2000).
Gascoigne et al., “Secretion of a chimeric T-cell receptor-immunoglobulin protein,”Proc. Natl. Acad. Sci. USA84:2936 (1987).
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,”J. Immunol. 148(5):1547 (1992).
Kurschner et al., “Construction, Purification, and Characterization of New InterferonY(IFNy) Inhibitor Proteins,”J. Biol. Chem267:9354 (1992).
Lesslauer et al., “Recombinant soluble tumor necrosis factor receptor proteins mice from lipopolysaccharide-induced lethality,”Eur. J. Immunol. 21:2883 (1991).
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med173:721 (1991).
Linsley et al., “CTLA-4 Is a Seond Receptor for the B Cell Activation Antigen B7,”J. Exp. Med. 174:561 (1991).
Louis et al., “Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity,”J. Biol. Chem. 276:(31)29485 (2001).
Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,”J. Exp. Med. 174:1483 (1991).
Ridgeway and Gorman, “Expression and Activity of IgE Receptor Alpha Chain-IgG Chimeric Molecules,”J. Cell. Biol115, Abstract No. 1448 (1991).
Root et al., “Protein Design of an HIV-1 Entry Inhibitor,”Science291:884 (2001).
Stamenkovic et al., “The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and α2-6 Sialytransferase, CD75, on B Cells,”Cell66:1133 (1991).
Traunecker et al., “Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules,”Nature339:68 (1989).
Watson et al., “A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules,”J. Cell. Biol. 110:2221 (1990).
Watson et al., “Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimaera,”Nature349:164 (1991).
Zettmeissl et al., “Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins,”DNA Cell Biol. USA9:347 (1990).
Zheng et al., “Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccha

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immunoglobulin chimeric monomer-dimer hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin chimeric monomer-dimer hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin chimeric monomer-dimer hybrids will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3921963

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.